Ignite Creation Date:
2024-05-06 @ 5:54 PM
Last Modification Date:
2024-10-26 @ 2:38 PM
Study NCT ID:
NCT05478239
Status:
RECRUITING
Last Update Posted:
2023-08-15
First Post:
2022-07-25
Brief Title:
ArtemiCoffee in Patients With Rising PSA
Sponsor:
Zin W Myint
Organization:
University of Kentucky
Study Overview
Official Title:
Phase II Trial of ArtemiCoffee for Men With Biochemical Recurrence of Prostate Cancer After Initial Local Therapy
Status:
RECRUITING
Status Verified Date:
2024-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Until now clinicians have been challenged to improve the treatment of biochemically recurrent BCR prostate cancer in which prostatic specific antigen PSA rises without radiological or clinical progression years after localized treatment radical prostatectomy or radiation therapy with or without hormonal treatment Approximately 50-90 of men with high-risk prostate cancer will experience a BCR Artesunate has demonstrated anti-tumor activity in both in vivo and in vitro cell lines It is hypothesized that Artemisia annua Aa coffee has the potential to decrease rising PSA among patients with biochemical recurrence of prostate cancer
Detailed Description:
This is an open-labeled phase II study of Artemisia annua Aa decaf coffee in patients with biochemical recurrence of prostate cancer
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None